Seana Carson - 27 Feb 2026 Form 4 Insider Report for Bausch Health Companies Inc. (BHC)

Role
EVP, General Counsel
Signature
/s/ Brianna M. Dorsi attorney-in-fact
Issuer symbol
BHC
Transactions as of
27 Feb 2026
Net transactions value
-$1,142,870
Form type
4
Filing time
03 Mar 2026, 17:43:08 UTC
Previous filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Carson Seana EVP, General Counsel 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER /s/ Brianna M. Dorsi attorney-in-fact 03 Mar 2026 0001923756

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHC Common Shares, No Par Value Tax liability $156,113 -26,326 -3.3% $5.93 782,932 27 Feb 2026 Direct F1
transaction BHC Common Shares, No Par Value Sale $39,628 -6,856 -0.88% $5.78 776,076 02 Mar 2026 Direct F2
transaction BHC Common Shares, No Par Value Tax liability $100,989 -16,973 -2.2% $5.95 759,103 02 Mar 2026 Direct F3
transaction BHC Common Shares, No Par Value Other $820,636 -137,922 -18% $5.95 621,181 02 Mar 2026 Direct F4
transaction BHC Common Shares, No Par Value Sale $25,503 -4,420 -0.71% $5.77 616,761 03 Mar 2026 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
F2 Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.
F3 This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
F4 Reflects the disposition in cash as contemplated by paragraph 7(1)(b) of the Income Tax Act (Canada) of 137,922 performance share unit awards originally granted to the Reporting Person under the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan on March 2, 2023, which, as previously reported on February 11, 2026, were earned, on February 9, 2026, upon certification by the Talent and Compensation Committee (the "Committee") of the Board of Directors of the Issuer of the level of achievement of the applicable performance metrics, but remained subject to service-based vesting. As disclosed in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 2, 2026, the Committee subsequently took action to provide for the payment of such earned performance share unit awards in cash rather than Issuer common stock upon vesting. The disposition in cash is exempt under Rule 16b-3(e).
F5 Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 7, 2025.